ArticleJournal of medical virology2026
Sensitive and Rapid Dual One-Tube Recombinase Aided PCR Assays for the Simultaneous Detection of Cytomegalovirus, Epstein-Barr Virus, Human Herpesvirus 6, and Herpes Simplex Virus 1/2 in Whole Blood From Children Undergoing Hematopoietic Stem Cell Transplantation.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Early, rapid, and sensitive detection of cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), and herpes simplex virus Types 1/2 (HSV-1/2) is critical for improving clinical outcomes in pediatric hematopoietic stem cell transplantation (HSCT). A dual one-tube recombinase-aided PCR (DO-RAP) assay was developed for the simultaneous detection of these viruses. The analytical sensitivity and specificity of the assay were evaluated and subsequently validated using 70 clinical whole blood samples. The DO-RAP assay demonstrated limits of detection (LOD) of two copies/reaction for CMV and HHV-6, 7 copies/reaction for EBV, and three copies/reaction for HSV-1/2. The total detection time was 62 min. In whole blood samples, DO-RAP demonstrated 100% sensitivity relative to qPCR, and identified 37 additional positive cases among qPCR-negative samples. DO-RAP exhibited higher sensitivity than qPCR for monitoring viral status before HSCT, at 0-30 days post-HSCT, and at 31-60 days post-HSCT, enabling earlier detection of CMV, EBV, HHV-6, and HSV-1/2 in recipients. During donor screening, DO-RAP also identified one additional CMV-positive and EBV-positive case compared with qPCR. The DO-RAP assay enables rapid and accurate detection of low-level viral infections in whole blood samples from HSCT settings, providing a valuable tool for routine monitoring of HSCT-associated viral infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.